Who Supplies Meropenem to India from SWITZERLAND

Importing finished pharmaceutical formulations containing Meropenem into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each batch of the formulation must be registered with the CDSCO, which involves submitting Form CT-20/40/41, along with the necessary documentation, including a Certificate of Pharmaceutical Product (CoPP), Certificate of Analysis (CoA), and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the workload of the CDSCO. Meropenem formulations under HS Code 30049099 are subject to these registration requirements.

Imported Meropenem formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a CoA, confirming compliance with the Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to ensure the product's efficacy and safety under Indian climatic conditions. Port inspections by customs drug inspectors are mandatory to verify the authenticity and quality of the imported formulations.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, including Meropenem. The introduction of the Production Linked Incentive (PLI) scheme has encouraged domestic manufacturing, potentially affecting the volume of imported formulations. Bilateral agreements between India and Switzerland have facilitated smoother trade processes, but importers must stay updated on any policy changes that may impact import procedures.

India imports finished Meropenem formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for Meropenem formulations is limited, leading to a reliance on imports to fulfill market needs. The Indian market for Meropenem formulations is substantial, with a growing demand due to the increasing incidence of infections requiring such treatments.

The import duty structure for Meropenem formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) is 12%. There are no exemptions or concessional rates for imports from Switzerland. The total landed duty is approximately 17.10%.

India sources Meropenem formulations from Switzerland due to the high quality and reliability of Swiss pharmaceutical products. Swiss manufacturers offer patented formulations and specialized dosage forms that are not available from other suppliers. While other countries like China, Germany, and the US also supply Meropenem formulations, Switzerland's reputation for quality and innovation gives it a competitive edge in the Indian market.

India imports Meropenem formulations from Switzerland due to the availability of patented formulations, specialized dosage forms, and technology-licensed products. Swiss manufacturers provide specific formulations that are not produced domestically, fulfilling a critical need in the Indian market.

Compared to other origins like China, the European Union, and the United States, Switzerland offers superior quality, regulatory compliance, and reliability in the supply of Meropenem formulations. While other countries may offer lower prices, Switzerland's unique advantage lies in its consistent product quality and adherence to international standards.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to global supply chain issues, highlighting the need for strategic sourcing and risk management.

1. 1Engage in dual-sourcing strategies to mitigate supply chain risks.
2. 2Implement robust inventory planning to ensure consistent product availability.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Establish clear Minimum Order Quantities (MOQs) with suppliers to optimize procurement efficiency.
5. 5Conduct thorough supplier qualification processes to ensure compliance with quality and regulatory standards.

1. 1Obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT).
2. 2Register each batch of Meropenem formulations with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form CT-20/40/41.
3. 3Provide a Certificate of Pharmaceutical Product (CoPP) and Certificate of Analysis (CoA) for each batch.
4. 4Submit stability data adhering to ICH Zone IV guidelines.
5. 5Ensure compliance with all CDSCO regulations and guidelines for pharmaceutical imports.

1. 1Certificate of Pharmaceutical Product (CoPP).
2. 2Certificate of Analysis (CoA) for each batch.
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for the formulation.
5. 5Stability data adhering to ICH Zone IV guidelines.
6. 6Free Sale Certificate.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors collect samples of each batch of Meropenem formulations for testing at CDSCO-approved laboratories. The testing process includes verifying compliance with the Indian Pharmacopoeia standards and assessing the stability data. If a batch fails to meet the required standards, it may be rejected, and the importer could face penalties. Common quality issues from Swiss imports are rare but can include discrepancies in labeling or packaging.

Importers must renew their CDSCO registration annually and comply with periodic audits in Switzerland to ensure continued adherence to Good Manufacturing Practices (GMP). Change control procedures must be in place to manage any modifications in the formulation or manufacturing process. Pharmacovigilance systems should be established for post-import monitoring of adverse events. Import records must be maintained as per the Drug and Cosmetics Act for regulatory compliance.